Displaying 81 - 90 of 243
Alternative Name: Antiestrogen ICI 182780; Fulvestrant
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Permanent
Delivery Method: Intrauterine
Developer: Femasys Inc
Development Stage: Phase I
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium, APCOR R&M, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
Alternative Name: Fibroplant LNG14 (also LNG 20)
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
Development Phase: Limited Market Availability
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Meril Life Science Private Ltd
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Prosan International B.V.
Development Stage: Marketed
Development Phase: Limited Market Availability
User: Male
Hormonal: No
Duration Type: Permanent
Delivery Method: Injectable
Developer: University of Washington, Focused Scientific
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Development Stage: Compound ID/Selection
Development Phase: Discovery and Early Development
User: Female
Hormonal: Yes
Delivery Method: Injectable
Developer: University of Mumbai
Development Stage: Pre-clinical
Development Phase: Pre-Clinical and Clinical Development
Alternative Name: Sperm glycolytic enzyme
Target
Hormonal: No
Developer: University of North Carolina at Chapel Hill, NICHD
Development Stage: Target Validation
Development Phase: Discovery and Early Development

Pages

Displaying 11 - 20 of 70
Alternative Name: ATPase Plasma Membrane Calcium Transporting 4, PMCA4, Plasma Membrane Calcium-Transporting ATPase 4, PMCA4b, PMCA4x, Matrix-Remodeling-Associated Protein 1, Sarcolemmal Calcium Pump, EC 7.2.2.10, EC 3.6.3.8, EC 3.6.3
Target
User: Female, Male
Hormonal: No
Development Stage: Target Identification
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Norfolk State University
Development Stage: Lead Optimization
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal, Other
Developer: University of Cincinnati
Development Stage: Lead Optimization
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Subdermal
Developer: Murdoch University
Development Stage: Prototype Development
Alternative Name: Bromodomain Testis Associated, Cancer/Testis Antigen 9, Bromodomain Testis-Specific Protein, Bromodomain, Testis-Specific, RING3-Like Protein, CT9, SPGF21, BRD6
Target
User: Male
Hormonal: No
Delivery Method: Injectable, Oral
Development Stage: Lead Optimization
User: Male
Hormonal: No
Delivery Method: Oral
Developer: Bar-Ilan University
Development Stage: Compound ID/Selection
Alternative Name: Calcium Binding Tyrosine Phosphorylation Regulated, Cancer/Testis Antigen 88, Calcium-Binding Tyrosine Phosphorylation-Regulated Protein, Testis-Specific Calcium-Binding Protein CBP86, Calcium-Binding Protein 86, Fibrousheathin II, Fibrousheathin-2, CBP86, FSP-2, CT88, FSP2
Target
User: Female, Male
Hormonal: No
Development Stage: Target Validation
Alternative Name: Calrecticulin 3, Calsperin, Cancer/Testis Antigen 93, Calreticulin-2, CRT2, Testis Secretory Sperm-Binding Protein Li 226n, CMH19, CT93
Target
User: Male
Hormonal: No
Development Stage: Target Validation
Target
User: Female, Male
Hormonal: No
Duration Type: Short-acting, Pericoital, Emergency
Developer: Hydra Biosciences, University of Minnesota, University of California at Berkeley, Harvard University, Dare BioScience Inc.
Development Stage: Lead Optimization
Alternative Name: Cyclin-dependent kinases (CDKs)
Target
User: Male
Hormonal: Yes
Developer: University of Kansas Medical Center, University of Minnesota, Moffitt Cancer Center at University of South Florida
Development Stage: Target Identification

Pages

Displaying 101 - 110 of 121
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Shanghai Institute of Planned Parenthood Research (SIPPR)
Development Stage: Pre-clinical
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: FHI 360
Development Stage: Phase I
Alternative Name: Hormonal Intrauterine Ball
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: OCON Medical Ltd.
Development Stage: Pre-clinical
Alternative Name: NSP-989; NSP-989 COMBO; Tanaproget COMBO; WAY-166989
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Oral
Developer: Ligand Pharmaceuticals, Inc.
Development Stage: Phase II
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Alternative Name: Tenofovir Disoproxil Fumarate (TDF) + Levonorgestrel Vaginal Ring
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Albert Einstein College of Medicine, NIAID, Northwestern University
Development Stage: Phase I
Alternative Name: Testicular heat supplementation
User: Male
Hormonal: No
Duration Type: Short-acting
Delivery Method: Testicular
Developer: University of California at Los Angeles
Development Stage: Phase II
User: Male
Hormonal: No
Duration Type: Permanent, Short-acting
Delivery Method: Testicular
Developer: Parsemus Foundation, University of Bari, University of California, University of North Carolina at Chapel Hill
Development Stage: Pre-clinical
Alternative Name: TU; Aveed
User: Male
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Bayer HealthCare, National Research Institute for Family Planning in Beijing
Development Stage: Phase III
Alternative Name: TV-46046
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Teva Branded Pharmaceutical Products R&D, Inc.
Development Stage: Phase I

Pages

Displaying 31 - 40 of 52
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Innova Quality S.A.S
Development Stage: Marketed
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Transdermal
Developer: Allergan
Development Stage: Regulatory
Alternative Name: Woman's Condom (WC)
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Shanghai Dahua Medical Apparatus Co., Ltd, PATH
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: Yes
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Contrel Research, Belgium
Development Stage: Regulatory
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Injectable
Developer: Helm Pharmaceuticals, Fresenius Kabi
Development Stage: Marketed
Alternative Name: Amphora® Gel, lactic acid, citric acid, and potassium bitartrate
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Vaginal Gel
Developer: Evofem Biosciences, Inc.
Development Stage: SRA/WHO PQ Approved
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: Tianjin Condombao Medical Polyurethane Tech. Co. Ltd
Development Stage: SRA/WHO PQ Approved
Alternative Name: Pregna PPIUD T Cu 380A
User: Female
Hormonal: No
Duration Type: Long-acting
Delivery Method: Intrauterine
Developer: Pregna International Limited
Development Stage: SRA/WHO PQ Approved
Alternative Name: Progestin Vaginal Ring (PVR)
User: Female
Hormonal: Yes
Duration Type: Short-acting
Delivery Method: Vaginal Ring
Developer: Population Council, Grunenthal
Development Stage: Marketed
Alternative Name: VA w.o.w.
User: Female
Hormonal: No
Duration Type: Pericoital
Delivery Method: Barrier
Developer: HLL Lifecare Limited, IXu LLC
Development Stage: SRA/WHO PQ Approved

Pages

CSV